Apelin inhibits insulin secretion in pancreatic β-cells by activation of PI3-kinase-phosphodiesterase 3B

Endocrine Research

Volumn 34, Issue 4, 2009, Pages 142-154

  Guo, Lin ^a   Li, Qiang ^a   Wang, Wei ^a   Yu, Ping ^a   Pan, Hongyan ^a   Li, Pengjie ^a   Sun, Yuqian ^a   Zhang, Jinchao ^a  

^a Medical University   (China)

Author keywords

Apelin; CAMP; GLP 1; Insulin; PDE3B; PI3K

Indexed keywords

8 BROMO CYCLIC AMP; APELIN; CYCLIC AMP; CYCLIC AMP DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IIIB; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOWN-REGULATION; ENZYME ACTIVATION; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE INHIBITORS; RATS;

EID: 72949111358     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800903287079     Document Type: Article

References (27)

1. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251:471-476.
2. Falcão-Pires I, Leite-Moreira A. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol 2005; 24:1263-1276.
3. O'Dowd B, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136:355-360.
4. Carpéné C, Dray C, Attané C, et al. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem 2007; 63:359-373.
5. Fan X, Zhou N, Zhang X, et al. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry 2003; 42:10163-10168.
6. Tatemoto K, Takayama K, Zou M, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99:87-92.
7. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006; 12:RA112-RA119.
8. Kleinz M, Davenport A. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107:198-211.
9. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006; 41:798-806.
10. Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, Epelbaum J, Bluet-Pajot M, Llorens-Cortes C. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. Am J Physiol Endocrinol Metab 2007; 292:E7-15.
11. Lee D, George S, O'Dowd B. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006; 27:190-194.
12. Japp A, Newby D. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008; 75:1882-1892.
13. Medhurst A, Jennings C, Robbins M, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84:1162-1172.
14. Zhong J, Yu X, Huang Y, Yung L, Lau C, Lin S. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 2007; 74:388-395.
15. Valle A, Hoggard N, Adams A, Roca P, Speakman J. Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice. J Neuroendocrinol 2008; 20:79-84.
16. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146:1764-1771.
17. Castan-Laurell I, Vítkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 2008; 158:905-910.
18. Heinonen M, Purhonen A, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005; 130:7-13.
19. Sörhede Winzell M, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131:12-17.
20. Walz H, Wierup N, Vikman J, et al. Beta-cell PDE3B regulates Ca2+-stimulated exocytosis of insulin. Cell Signal 2007; 19:1505-1513.
21. Waddleton D, Wu W, Feng Y, et al. Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets. Biochem Pharmacol 2008; 76:884-893.
22. Cong L, Chen K, Li J, et al. Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes. Biochem J 2007; 403:519-525.
23. Yan C, Zhao A, Bentley J, Loughney K, Ferguson K, Beavo J. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci USA 1995; 92:9677-9681.
24. Whitman M, Kaplan D, Schaffhausen B, Cantley L, Roberts T. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985; 315:239-242.
25. Fournier A, Achard J, Mazouz H, et al. Could angiotensin II type I receptor antagonists have a superior beneficial effect than that of angiotensin II converting enzyme inhibitors with respect to the risk of cerebrovascular accident? Arch Mal Coeur Vaiss 1999; 92:997-1000.
26. Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114:544-548.
27. Härndahl L, Jing X, Ivarsson R, et al. Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J Biol Chem 2002; 277:37446-37455.